guest ::
| Home > Publications database > Design, Synthesis and Biological Evaluation of β-Peptoid-Capped HDAC Inhibitors with Anti-Neuroblastoma and Anti-Glioblastoma Activity > print |
| Home > Publications database > Design, Synthesis and Biological Evaluation of β-Peptoid-Capped HDAC Inhibitors with Anti-Neuroblastoma and Anti-Glioblastoma Activity > print |
| 001 | 856855 | ||
| 005 | 20210129235417.0 | ||
| 024 | 7 | _ | |a 10.1039/C8MD00454D |2 doi |
| 024 | 7 | _ | |a 2040-2503 |2 ISSN |
| 024 | 7 | _ | |a 2040-2511 |2 ISSN |
| 024 | 7 | _ | |a altmetric:50982181 |2 altmetric |
| 024 | 7 | _ | |a WOS:000475806000003 |2 WOS |
| 037 | _ | _ | |a FZJ-2018-06194 |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |a Reßing, Nina |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Design, Synthesis and Biological Evaluation of β-Peptoid-Capped HDAC Inhibitors with Anti-Neuroblastoma and Anti-Glioblastoma Activity |
| 260 | _ | _ | |a Cambridge |c 2019 |b RSC Publ. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1564051694_26959 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Histone deacetylases (HDACs) have been identified as promising epigenetic drug targets for the treatment of neuroblastomaand glioblastoma. In this work, we have rationally designed a novel type of peptoid‐based histone deacetylase inhibitors(HDACi). A mini library of β‐peptoid‐capped HDACi was synthesized using a four‐step protocol. All compounds were screenedin biochemical assays for its inhibition of HDAC1 and HDAC6 and docking studies were performed to rationalize the observedselectivity profile. The synthesized compounds were further examined for tumor cell‐inhibitory activity against a panel ofneuroblastoma and glioblastoma cell lines. In particular, non‐selective compounds with potent activity against HDAC1 andHDAC6 showed strong antiproliferative effects. The most promising HDACi, compound 6i, displayed submicromolar tumorcell‐inhibitory potential (IC50: 0.21 – 0.67 μM) against all five cancer cell lines investigated and exceeded the activity of theFDA‐approved HDACi vorinostat. |
| 536 | _ | _ | |a 511 - Computational Science and Mathematical Methods (POF3-511) |0 G:(DE-HGF)POF3-511 |c POF3-511 |f POF III |x 0 |
| 536 | _ | _ | |a Forschergruppe Gohlke (hkf7_20170501) |0 G:(DE-Juel1)hkf7_20170501 |c hkf7_20170501 |f Forschergruppe Gohlke |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Marquardt, Viktoria |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Gertzen, Christoph |0 P:(DE-Juel1)174133 |b 2 |u fzj |
| 700 | 1 | _ | |a Schöler, Andrea |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Schramm, Alexander |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Kurz, Thomas |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Gohlke, Holger |0 P:(DE-Juel1)172663 |b 6 |u fzj |
| 700 | 1 | _ | |a Aigner, Achim |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Remke, Marc |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Hansen, Finn Kristian |0 P:(DE-HGF)0 |b 9 |e Corresponding author |
| 773 | _ | _ | |a 10.1039/C8MD00454D |g p. 10.1039.C8MD00454D |0 PERI:(DE-600)2545949-1 |n 7 |p 1109-1115 |t MedChemComm |v 10 |y 2019 |x 2040-2511 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/856855/files/beta%20peptoids%20revision.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/856855/files/c8md00454d.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/856855/files/beta%20peptoids%20revision.pdf?subformat=pdfa |x pdfa |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/856855/files/c8md00454d.pdf?subformat=pdfa |x pdfa |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:856855 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)174133 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)172663 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |1 G:(DE-HGF)POF3-510 |0 G:(DE-HGF)POF3-511 |2 G:(DE-HGF)POF3-500 |v Computational Science and Mathematical Methods |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |l Supercomputing & Big Data |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a National-Konsortium |0 StatID:(DE-HGF)0430 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MEDCHEMCOMM : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)JSC-20090406 |k JSC |l Jülich Supercomputing Center |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)ICS-6-20110106 |k ICS-6 |l Strukturbiochemie |x 1 |
| 920 | 1 | _ | |0 I:(DE-Juel1)NIC-20090406 |k NIC |l John von Neumann - Institut für Computing |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)JSC-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 980 | _ | _ | |a I:(DE-Juel1)NIC-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|